U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07727473) titled 'Preoperative Semaglutide Prior to Radical Prostatectomy' on May 13.
Brief Summary: In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide prior to radical prostatectomy in participants with intermediate risk prostate cancer will be investigated. Semaglutide will be administered according to the FDA-approved label for chronic weight management and participants will be dosed with a weekly subcutaneous injection. The primary aim of this trial is to explore the tumor biological activity of semaglutide in these participants....